EPS (diluted) · 2023–2025
Genmab diluted EPS
15.37−12.3% · FY2025
Genmab (GMAB) reported 15.37 in diluted EPS for fiscal 2025, −12.3% year on year.
EPS (diluted) — Diluted earnings per share is net income divided by the share count after every option and convertible is counted as if exercised. It is the conservative version of EPS.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2023–2025 compound annual growth +26.7%
Figures are reported under IFRS, in US dollars.
EPS (diluted) at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Genmab diluted EPS |url=https://companiesranked.com/en/company/genmab/eps |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Genmab diluted EPS. CompaniesRanked. https://companiesranked.com/en/company/genmab/epsBibTeX
@misc{companiesranked-en-company-genmab-eps-2026,
author = {{CompaniesRanked}},
title = {{Genmab diluted EPS}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/genmab/eps}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001434265-26-000014 · February 17, 2026
{{cite web |title=Genmab diluted EPS — 20-F (0001434265-26-000014) |url=https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/gmab-20251231_d2.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.